Dr. Reddy's Laboratories on Track for Largest Percent Increase Since May 2022 — Data Talk
Dr. Reddy's Laboratories Ltd. Sponsored ADR (RDY) is currently at $74.12, up $3.20 or 4.51%
--Would be highest close since March 18, 2024, when it closed at $75.49
--On pace for largest percent increase since May 20, 2022, when it rose 7.17%
--Snaps a two day losing streak
--Up 1.05% month-to-date; on pace for best month since Feb. 2024, when it rose 6.71%
--Up 6.52% year-to-date
--Down 4.47% from its all-time closing high of $77.59 on Feb. 23, 2024
--Up 22.35% from 52 weeks ago (April 27, 2023), when it closed at $60.58
--Down 4.47% from its 52-week closing high of $77.59 on Feb. 23, 2024
--Up 38.96% from its 52-week closing low of $53.34 on May 18, 2023
--Traded as high as $74.33; highest intraday level since April 1, 2024, when it hit $74.44
--Up 4.81% at today's intraday high; largest intraday percent increase since Jan. 31, 2024, when it rose as much as 6.07%
All data as of 12:53:03 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 25, 2024 13:11 ET (17:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations